ArticleJournal of clinical medicine2019
Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts Study.
Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis.International urology and nephrology · 2021Pooled it
- Decreased Hemoglobin Concentration and Iron Metabolism Disorder in Periodontitis: Systematic Review and Meta-Analysis.Frontiers in physiology · 2019Pooled it
- Erythroferrone is associated with the hepcidin-to-ferritin ratio and cardiovascular mortality in chronic kidney disease.Clinical kidney journal · 2026Article
- Erythroferrone, Hepcidin, and Erythropoietin in Chronic Kidney Disease: Associations with Hemoglobin and Renal Function.Journal of clinical medicine · 2025Article
- Article
- Erythroferrone in focus: emerging perspectives in iron metabolism and hematopathologies.Blood science (Baltimore, Md.) · 2024Review
- RNAseq of INOCA patients identifies innate, invariant, and acquired immune changes: potential autoimmune microvascular dysfunction.Frontiers in cardiovascular medicine · 2024Article
- Iron status and anemia control are related to peritoneal membrane properties in peritoneally dialyzed patients.Frontiers in medicine · 2023Article
- A Multimodal Deep Learning Approach to Predicting Systemic Diseases from Oral Conditions.Diagnostics (Basel, Switzerland) · 2022Article
- Erythrocyte indices and localized stage II/III periodontitis in military young men and women: CHIEF oral health study.BMC oral health · 2022Article
- In-depth review: is hepcidin a marker for the heart and the kidney?Molecular and cellular biochemistry · 2021Review
- Serum Erythroferrone During Pregnancy Is Related to Erythropoietin but Does Not Predict the Risk of Anemia.The Journal of nutrition · 2021Observational
- Intravenous iron therapy and the cardiovascular system: risks and benefits.Clinical kidney journal · 2021Review
- Erythroferrone Expression in Anemic Rheumatoid Arthritis Patients: Is It Disordered Iron Trafficking or Disease Activity?Journal of inflammation research · 2021Article
- Differentiating iron-loading anemias using a newly developed and analytically validated ELISA for human serum erythroferrone.PloS one · 2021Article
- Iron and Chronic Kidney Disease: Still a Challenge.Frontiers in medicine · 2020Review
- New diagnostic tools for delineating iron status.Hematology. American Society of Hematology. Education Program · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythroferrone (ERFE) is a hepcidin inhibitor whose synthesis is stimulated by erythropoietin, which increases iron absorption and mobilization. We studied the association between serum ERFE and mortality and non-fatal cardiovascular (CV) events in a cohort of 1123 hemodialysis patients and in a cohort of 745 stage 1-5 chronic kidney disease (CKD) patients. Erythroferrone was measured by a validated enzyme-linked immunosorbent assay (ELISA). In the hemodialysis cohort, serum ERFE associated directly with erythropoiesis stimulating agents (ESA) dose (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.